Evogen, UCB Announce Collaboration
News Dec 07, 2016
Evogen, and UCB have announced a collaboration for further development of EvoScoreTM START, Evogen's new proteomics-based blood test designed to accurately distinguish epileptic seizures from other events.
The accurate diagnosis of epilepsy seizures remains a challenge to physicians and patients. Current diagnostic tools can be cumbersome, expensive and may have sub-optimal accuracy. The considerable time and cost of current diagnostic methods could pose a burden to patients and healthcare systems, and may also result in treatment delays for some epilepsy patients and inappropriate treatment for others.
The EvoScore START test is a new approach to the diagnosis of epileptic seizures. It analyzes the ratio and concentration of key protein biomarkers in a simple blood test format to determine whether an event was actually a seizure, with sensitivity and specificity of 90% or more. It is estimated that only about 15% of suspected seizure-like events are actual epileptic seizures, yet there are no easily available tools that can definitively distinguish a seizure from another event.
“Evogen aims to be the leader in neurology proteomic and genomic testing, and we believe that EvoScore START has the potential to revolutionize the diagnosis of epilepsy,” said Todd Wallach, president and chief executive officer of Evogen. “We are accordingly thrilled to work with epilepsy leader UCB to conduct further development of this innovative biomarker-based blood test. We have always admired UCB’s long-standing commitment to the epilepsy field and look forward to UCB’s expert help in further refining this important new diagnostic tool for epilepsy patients and their healthcare providers.”
“UCB is excited about the potential of better diagnostic tests to improve individual experiences for people with epilepsy,” explained Jeff Wren, Head of UCB’s Neurology Patient Value Unit. “We believe the availability of more accurate and accessible diagnostics, like EvoScore START, may improve time to care for epilepsy patients and could deliver additional value across the broader healthcare system.”
Original story from Evogen. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.
Algorithm Unearths Over 1000 Antibiotic Proteins in a Few HoursNews
The algorithm identified 10 times more peptide variations than all previous discoveries combined, aiding the hunt for new antibiotics.READ MORE
Protein That Helps Keep Breast Cancer Dormant IdentifiedNews
A protein kinase that stops breast cancer cells growing and spreading has been outlined in new research.READ MORE
Barrier to Liquid Biopsies Overcome with Blood Stabilization TechniqueNews
A new technique that prolongs the lifespan of blood samples could be a breakthrough for liquid biopsy assays.READ MORE